Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A prescriber-level guide to bisphosphonate adverse-event management: GI toxicity, osteonecrosis of the jaw, atypical femur fractures, renal dosing, and drug holidays. Includes specific protocols, doses, and monitoring thresholds.
Read clinical reviewA prescriber-level guide to bisphosphonate pharmacology, indication coding, prior authorization strategy, and step-therapy navigation for alendronate, risedronate, zoledronic acid, and ibandronate.
Read clinical reviewA prescriber-level monograph covering bisphosphonate pharmacology, dosing, efficacy data, adverse effects, monitoring, and clinical decision points for osteoporosis management.
Read clinical reviewA clinical-level review of bisphosphonate drug-drug interactions, pharmacokinetics, dosing rules, and prescribing guidance for alendronate, zoledronic acid, risedronate, ibandronate, and pamidronate, with a full DDI table and primary-source citations.
Read clinical reviewA prescriber-level guide to bisphosphonate monitoring, covering baseline labs, on-treatment surveillance, renal function tracking, dental screening, and when to consider a drug holiday.
Read clinical reviewA clinician-focused summary of bisphosphonate prescribing in special populations including renal impairment, geriatric patients, premenopausal women, pediatric use, and pregnancy. Includes dose adjustments, monitoring, and contraindications.
Read clinical reviewEvidence-based titration, drug holidays, and tapering protocols for bisphosphonates (alendronate, risedronate, zoledronic acid, ibandronate) in osteoporosis management, written for prescribers and pharmacists.
Read clinical reviewA prescriber-level guide to choosing between alendronate, risedronate, ibandronate, zoledronic acid, and pamidronate based on indication, renal function, adherence profile, and fracture-reduction evidence.
Read clinical review